ROIV
Roivant Sciences Ltd.
$33.84
-0.88
(-2.53%)
Mkt Cap
24.34B
Volume
4,400,134
52W Range
10.9-37
Sector
Healthcare
Beta
1.11
EPS (TTM)
-0.45
P/E Ratio
-64.42
Revenue (TTM)
8.26M
Rev Growth (5Y)
-19.1%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$91.67
Undervalued
strong signal
63.1% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 8.26M | 29.05M | 32.71M | 31.53M | 55.29M | 23.80M | 67.69M |
| Net Income | (299.77M) | (171.98M) | 4.35B | (1.01B) | (845.26M) | (809.23M) | 1.20B |
| EPS | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 | 1.75 |
| Free Cash Flow | (758.56M) | (844.05M) | (766.65M) | (856.08M) | (695.16M) | (557.94M) | (766.75M) |
| FCF / Share | -1.09 | -1.16 | -0.98 | -1.20 | -1.04 | -0.81 | -1.12 |
| Operating CF | (750.35M) | (839.45M) | (765.27M) | (843.39M) | (677.73M) | (552.14M) | (761.83M) |
| Total Assets | 5.73B | 5.44B | 7.22B | 2.39B | 2.59B | 2.69B | 2.48B |
| Total Debt | 107.44M | 100.17M | 499.75M | 481.40M | 283.89M | 244.98M | 180.88M |
| Cash & Equiv | 1.42B | 2.72B | 6.54B | 1.68B | 2.06B | 2.13B | 2.19B |
| Book Value | 4.53B | 4.69B | 5.97B | 1.16B | 1.66B | 1.90B | 2.03B |
| Return on Equity | -0.07 | -0.04 | 0.73 | -0.87 | -0.51 | -0.43 | 0.59 |
| Metric | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.52M | 2.00M | 1.57M | 2.17M | 7.57M | 9.02M | 4.47M | 7.99M | 28.93M | 15.56M | 3.65M | 21.62M |
| Net Income | 302.99M | (265.89M) | (113.52M) | (223.35M) | (206.47M) | 169.38M | (230.18M) | 95.30M | (151.12M) | 5.10B | (304.33M) | (291.82M) |
| EPS | 0.43 | -0.38 | -0.17 | -0.33 | -0.29 | 0.23 | -0.31 | 0.13 | -0.19 | 6.37 | -0.40 | -0.38 |
| Free Cash Flow | (165.08M) | (191.55M) | (193.51M) | (208.42M) | (173.38M) | (209.08M) | (267.80M) | (193.79M) | (108.81M) | (210.81M) | (196.70M) | (250.34M) |
| FCF / Share | -0.24 | -0.27 | -0.28 | -0.31 | -0.25 | -0.29 | -0.36 | -0.26 | -0.14 | -0.26 | -0.26 | -0.33 |
| Operating CF | (163.82M) | (196.48M) | (185.66M) | (204.38M) | (172.56M) | (207.25M) | (266.81M) | (192.83M) | (108.46M) | (210.45M) | (196.43M) | (249.93M) |
| Total Assets | 5.73B | 5.23B | 5.06B | 5.03B | 5.44B | 5.79B | 6.21B | 6.50B | 7.22B | 7.31B | 2.07B | 2.14B |
| Total Debt | 107.44M | 207.44M | 98.85M | 99.69M | 100.17M | 100.31M | 52.71M | 379.06M | 499.75M | 506.58M | 497.98M | 492.63M |
| Cash & Equiv | 1.42B | 1.48B | 1.24B | 1.24B | 2.72B | 1.99B | 1.96B | 5.68B | 6.54B | 6.67B | 1.41B | 1.44B |
| Book Value | 4.53B | 4.27B | 4.36B | 4.35B | 4.69B | 5.19B | 5.15B | 5.44B | 5.97B | 6.09B | 948.53M | 910.73M |
| Return on Equity | 0.07 | -0.06 | -0.03 | -0.05 | -0.04 | 0.03 | -0.04 | 0.02 | -0.03 | 0.84 | -0.32 | -0.32 |
ROIV News
Bank of Nova Scotia Cuts Stake in Roivant Sciences Ltd. $ROIV
Allspring Global Investments Holdings LLC Buys New Stake in Roivant Sciences Ltd. $ROIV
Roivant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Immunovant to Report Financial Results for the First Quarter Ended June 30, 2026, and Provide Business Update on Thursday, August 6, 2026
Could Roivant Sciences Be a Multibagger Stock Over the Next 5 Years?
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy
Roivant Sciences Ltd. (ROIV) Q4 2025 Earnings Call Transcript